PARIS--(BUSINESS WIRE)--Regulatory News:
ABIVAX (Paris:ABVX) (Euronext Paris : FR0012333284 – ABVX), an innovative biotechnology company targeting the immune system to eliminate viral disease, today announces that Prof. Hartmut Ehrlich, M.D., CEO of ABIVAX, will attend the Jefferies 2016 London Healthcare Conference being held on November 16th and 17th at the Waldorf Hilton in London, UK.
The event will feature leading public and private companies from the pharmaceuticals, biotechnology, generics, consumer health, animal health, medical technology and healthcare services sectors. It will include concurrent tracks of company presentations, thematic panel discussions, and 1x1/small-group meetings.
ABIVAX’s lead product ABX464 is in Phase II clinical development for the treatment of HIV, and earlier this year started a second Phase IIa trial designed to demonstrate the long-lasting effect of ABX464. The product candidate has a unique mechanism that interrupts HIV replication and also targets HIV reservoir cells.
One-on-one meetings with Pr. Ehrlich can be arranged through Jefferies.
About ABIVAX (www.abivax.com)
ABIVAX is an innovative biotechnology company focused on
targeting the immune system to eliminate viral disease. ABIVAX leverages
three technology platforms for drug discovery: an anti-viral, an immune
enhancement, and a polyclonal antibody platform. ABX464, its most
advanced compound, is currently in Phase II clinical trials and is a
first-in-class oral small anti-viral molecule which blocks HIV
replication through a unique mechanism of action. In addition, ABIVAX is
advancing multiple preclinical candidates against additional viral
targets (i.e. Chikungunya, Ebola, Dengue) as well as an immune enhancer,
and several of these compounds are planned to enter clinical development
within the next 18 months. A recently updated corporate presentation,
which includes a timeline for the company’s anticipated news flow, is
available at www.abivax.com.
Follow
us on Twitter @ABIVAX_
